oral ROR_ nuclear receptor agonist
450 mg BID, phase I/II, cancer
from change in MoA of ROR_ antagonist + opt.
Journal of Medicinal Chemistry
The Lycera ROR gamma agonist, cintirorgon (LYC-55716), is a first-in-class phase 1b clinical candidate for cancer immunotherapy (in combination with pembrolizumab in NSCLC). ROR gamma antagonists have been extensively…